-
-
-
PANTAKIND DSR CAP 10`S ₦2,006.50 -
DENON SOAP 75GM ₦1,753.25 -
GLYCIPHAGE SR 850MG TAB 10`S ₦865.25 -
Living Proof No Frizz Vanishing Oil 50ml ₦66,085.93 -
-
Sertaspor Cream, 50gm ₦34,500.00 -
ECT 90MG TABLET ₦2,681.25 -
Lacne Gel (15gm) (pack of 2) ₦3,300.00 -
SPECIAL BYO NIGHT 30ML ₦28,462.00 -
DIVAINE 100MG TAB 10`S ₦9,061.75 -
TOCASVIT 30CPR S/SUGAR ₦33,193.00 -
-
CALADROP LOTION ₦4,022.00
-
Sale
Angist SR 2.6 mgAngist SR 2.6 mg sublingual tablet is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery diseaseTheropeutic ClassNitrates: Coronary vasodilatorsPharmacologyAngist SR 2.6 mg forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle and result in vasodilatation.Dosage & Administration of Angist SR 2.6 mgOne sublingual tablet should be dissolved under the tongue at the first sign of an acute anginal attack. The dose may be repeated approximately every five minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, prompt medical attention is recommended.Interaction of Angist SR 2.6 mgPatients receiving antihypertensive drugs, beta-adrenergic blockers or phenothiazines and nitrates should be observed for possible additive hypotensive effects. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Concomitant use of nitrates and alcohol may cause hypotension. The vasodilatory and hemodynamic effects of Angist SR 2.6 mg may be enhanced by concomitant administration of aspirin. Patients receiving sublingual Angist SR 2.6 mg should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.ContraindicationsSublingual Angist SR 2.6 mg therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure and those with a known hypersensitivity to Angist SR 2.6 mg. Administration of Angist SR 2.6 mg is contraindicated in patients who are using sildenafil citrate since sildenafil citrate has been shown to potentiate the hypotensive effects of organic nitrates.Side Effects of Angist SR 2.6 mgHeadache which may be severe and persistent may occur immediately after use. Vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally.Pregnancy & LactationAngist SR 2.6 mg should be given to a pregnant woman only if clearly needed. It is not known whether Angist SR 2.6 mg is excreted in human milk.Precautions & WarningsOnly the smallest dose required for effective control of the acute anginal attack should be used. Excessive use may lead to the development of tolerance. This drug should be used with caution in patients who may be volume-depleted or are alredy hypotensive.Storage ConditionsStore in a cool and dry place away from light and heat. Keep all medicines out of the reach of children.Angist SR2.6 mg
Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00. -
SaleAngivas MR 35 mgAngivas MR 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugsPharmacologyAngivas MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angivas MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.Dosage & Administration of Angivas MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Dosage of Angivas MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Interaction of Angivas MR 35 mgNo drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.ContraindicationsTrimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson?s disease, parkinsonian symptoms, tremors, restless legs movement disorders, severe renal impairment.Side Effects of Angivas MR 35 mgTrimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and astheniaPregnancy & LactationThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.Precautions & WarningsTrimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Drug ClassesOther Anti-anginal & Anti-ischaemic drugsMode Of ActionAngivas MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angivas MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.PregnancyThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.
Angivas MR35 mg
Original price was: ₦275.00.₦247.50Current price is: ₦247.50. -
SaleAngivent MR 35 mgAngivent MR 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugsPharmacologyAngivent MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angivent MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.Dosage & Administration of Angivent MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Dosage of Angivent MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Interaction of Angivent MR 35 mgNo drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.ContraindicationsTrimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson?s disease, parkinsonian symptoms, tremors, restless legs movement disorders, severe renal impairment.Side Effects of Angivent MR 35 mgTrimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and astheniaPregnancy & LactationThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.Precautions & WarningsTrimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Drug ClassesOther Anti-anginal & Anti-ischaemic drugsMode Of ActionAngivent MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angivent MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.PregnancyThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.
Angivent MR35 mg
Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00. -
SaleAnin Plus 50 mg+12.5 mgThis is indicated for the treatment of hypertension. It is also indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.Theropeutic ClassCombined antihypertensive preparationsPharmacologyLosartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.Hydrochlorothiazide inhibits the reabsorption of Na in the distal tubules causing increased excretion of Na and water including K and hydrogen ions.Dosage & Administration of Anin Plus 50 mg+12.5 mgHypertension: Usual starting dose: 50/12.5 mg once daily. Titrate as needed to a maximum dose of 100/25 mg. Hypertensive Patients with Left Ventricular Hypertrophy: Not controlled on monotherapy: Initiate with 50/12.5 mg. Titrate as needed to a maximum of 100/25 mg. Dosing must be individualised. The usual starting dose of Losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured trough using once a day dosing is inadequate, a twice a day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily and can be given at doses of 12.5 to 25 mg. To minimise dose independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapyDosage of Anin Plus 50 mg+12.5 mgHypertension- The usual starting dose of 50/12.5 is one tablet once daily. For patients who do not respond adequately to one tablet the dosage may be increased to 100/25 once daily. A patient whose blood pressure is not adequately controlled with Losartan 100 mg monotherapy may be switched to this combination 100/12.5 once daily. In hypertensive patients with left ventricular hypertrophy initial dose is 50/12.5, if additional blood pressure reduction is needed, 100/12.5 may be given, followed by 100/25 if required. The maximum dose is 100/25 once daily. In general, the antihypertensive effect is attained within three weeks after initiation of therapy. No initial dosage adjustment of 50/12.5 is necessary for elderly patients. But maximum dose of 100/25 once daily dose should not be used as initial therapy in elderly patients. Severe Hypertension: The starting dose for initial treatment of severe hypertension is one tablet of 50/12.5 once daily. For patients who do not respond adequately to this dose after 2 to 4 weeks of therapy, the dosage may be increased to 100/25 once daily. The maximum dose is one tablet of 100/25 once daily. Administration of Anin Plus 50 mg+12.5 mgThis preparation may be administered with other antihypertensive agents. This may be administered with or without food.Interaction of Anin Plus 50 mg+12.5 mgLosartan Potassium: No significant drug-drug pharmacokinetic interactions have been found in interaction studies with Hydrochlorothiazide, Digoxin, Warfarin, Cimetidine and Phenobarbital. As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g. Spironolactone, Triamterene, Amiloride), potassium supplements, or salt substitutes containing potassium may lead to increase in serum potassium. As with other antihypertensive agents, the antihypertensive effect of Losartan may be blunted by the non-steroidal anti-inflammatory drug Indomethacin.Hydrochlorothiazide: When administered concurrently, the following drugs may interact with Thiazide diuretics: alcohol, barbiturates, or narcotics-potentiation of orthostatic hypotension may occur. Antidiabetic drugs (oral agents and Insulin): dosage adjustment of the antidiabetic drug may be required.Other antihypertensive drugs: additive effect or potentiation.Cholestyramine and colestipol resins: absorption of Hydrochlorothiazide is impaired in the presence of anionic exchange resinsContraindicationsThe combination of Losartan and Hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product. Because of the Hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.Side Effects of Anin Plus 50 mg+12.5 mgSide-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). Hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-II receptor antagonists. Vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, malaise, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including Henoch-Schonlein purpura)Pregnancy & LactationWhen pregnancy is detected, Losartan & Hydrochlorothiazide?should be discontinued as soon as possible. It is not known whether Losartan is excreted in human milk. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & Warnings Hypersensitivity: Angiooedema Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals Hypokalemia may rarely develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy Impaired renal function and Symptomatic hypotension Overdose Effects of Anin Plus 50 mg+12.5 mgLosartan Potassium: Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its metabolite can be removed by hemodialysis.Hydrochlorothiazide: The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia, may accentuate cardiac arrhythmias. The degree to which Hydrochlorothiazide is removed by hemodialysis has not been established.Storage ConditionsDo not store above 30?C. Keep out of the reach of children.Use In Special PopulationsUse in pediatric patients: The safety and effectiveness in paediatric patients have not been established.Use in patients with renal impairment: The usual regimens of therapy with Losartan & Hydrochlorothiazide may be followed as long as the patient?s creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so Losartan & Hydrochlorothiazide is not recommended.Patients with hepatic impairment: Losartan & Hydrochlorothiazide is not recommended for titration in patients with hepatic impairment because the appropriate 25 mg starting dose of losartan cannot be given.Drug ClassesCombined antihypertensive preparationsMode Of ActionAngiotensin II formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g. vascular smooth muscle, adrenal gland). In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT1 receptor. Neither Losartan nor its active metabolite inhibits ACE (kinase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of Sodium and Chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in Aldosterone secretion, increases in urinary Potassium loss, and decreases in serum Potassium. The renin-aldosterone link is mediated by angiotensin II, so co-administration of an angiotensin II receptor antagonist tends to reverse the Potassium loss associated with these diuretics.PregnancyAngiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohy dramnios have also been reported. Information on the use of angiotensin-II receptor antagonists in breastfeeding is limited. They are not recommended in breastfeeding and alternative treatment options, with better-established?safety information during breastfeeding, are available.Pediatric UsesUse in Patients with Renal Impairment: The usual regimens of therapy with 50/12.5 may be followed as long as the patient's creatinine clearance is >30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. In that case, hydrochlorothiazide is not recommended.Use in Patients with Hepatic Impairment: The combination of Losartan and Hydrochlorothiazide is not recommended for titration in patients with hepatic impairment because the appropriate 25 mg starting dose of Losartan cannot be given.Use in pediatric patients: The safety and effectiveness in pediatric patients have not been established.
Anin Plus50 mg+12.5 mg
Original price was: ₦330.00.₦297.00Current price is: ₦297.00. -
SaleAnin 50 mgHypertension: It is recommended to use Anin 50 mg to treat hypertension. It could be used with other antihypertensive medications or taken alone (eg. thiazide diuretics). Renal Protection in Type-2 Diabetic Patients with Proteinuria: In hypertensive type-2 diabetics with proteinuria, which is defined as urine albumin to creatinine ratio >300 mg/g, Anin 50 mg is advised to postpone the advancement of renal disease.Theropeutic ClassAngiotensin-ll receptor blockerPharmacologyThe first angiotensin II receptor blocker that is orally active without a peptide is Anin 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.Dosage & Administration of Anin 50 mgFor the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Anin 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.Dosage of Anin 50 mgFor the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Anin 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.Interaction of Anin 50 mgLevels of the Anin 50 mg active metabolite are decreased by rifampicin and fluconazole. The antihypertensive effects of hydrochlorothiazide and Anin 50 mg used together may be potentiated. Increases in serum potassium may result from the concurrent use of potassium-sparing diuretics (such as spironolactone, triamterene, and amiloride), potassium supplements, or salt substitutes containing potassium. The non-steroidal anti-inflammatory medicine indomethacin may lessen the antihypertensive effects of losartan. The risk of renal impairment is increased by the concurrent use of an ACE inhibitor, an angiotensin receptor antagonist, an anti-inflammatory medication, and a thiazide diuretic.ContraindicationsPregnant women and individuals who are hypersensitive to any ingredient in this medication should not use Anin 50 mg. Those with diabetes shouldn't take Aliskiren and Anin 50 mg together.Side Effects of Anin 50 mgAnin 50 mg side effects are minor and short-lived in nature. Dizziness, diarrhea, nasal congestion, coughing, and upper respiratory infections are the most frequent adverse effects. Fatigue, oedema, chest pain, nausea, headaches, and pharyngitis are other adverse effects.Pregnancy & LactationCategory D for pregnancies. If Anin 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Anin 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.Precautions & WarningsIn addition to increasing fetal and neonatal morbidity and mortality, the use of Anin 50 mg throughout the second and third trimesters of pregnancy decreases fetal renal function. Symptomatic hypotension may happen in people who are intravascularly volume-depleted (such as those taking high-dose diuretics). Patients with cirrhosis have a considerably higher plasma concentration of Anin 50 mg. Patients with renal impairment have experienced changes in renal function, including renal failure.Storage ConditionsKeep dry and away from heat and light. Keep out of children's reach.Drug ClassesAngiotensin-ll receptor blockerMode Of ActionThe first angiotensin II receptor blocker that is orally active without a peptide is Anin 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.PregnancyCategory D for pregnancies. If Anin 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Anin 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.
Anin50 mg
Original price was: ₦275.00.₦247.50Current price is: ₦247.50. -
SaleAnleptic CR 200 mgAnleptic CR 200 mg is indicated for- partial and secondary generalized tonic-clonic seizures Primary generalized tonic-clonic seizures Trigeminal neuralgia Prophylaxis of bipolar disorder Theropeutic ClassPrimary anti-epileptic drugsPharmacologyAnleptic CR 200 mg depresses activity in the nucleus ventralis of the thalamus, reduces synaptic propagation of excitatory impulses or decreases summation of temporal stimulation leading to neural discharge by limiting influx of Na ions across cell membrane or other unknown mechanisms. It stimulates the release of antidiuretic hormone (ADH) and potentiates its action in promoting reabsorption of water.Dosage & Administration of Anleptic CR 200 mgEpilepsy: Adults and children over 12 years of age- Initial: Either 200 mg b.i.d. for tablets and controlled release tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Children 12-15 years of age- Dosage generally should not exceed 1000 mg daily, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: usually 800-1200 mg daily. Children 6-12 years of age- Initial: Either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d.or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance:usually 400-800 mg daily. Children under 6 years of age- Initial: 10-20 mg/kg/day b.i.d.or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Anleptic CR 200 mg for use at doses above 35 mg/kg/24 hours can be made. Combination therapy: Anleptic CR 200 mg may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased.Trigeminal Neuralgia: Initial: On the first day,either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or controlled release tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.Dosage of Anleptic CR 200 mgEpilepsy: Adults and children over 12 years of age- Initial: Either 200 mg b.i.d. for tablets and controlled release tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Children 12-15 years of age- Dosage generally should not exceed 1000 mg daily, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: usually 800-1200 mg daily. Children 6-12 years of age- Initial: Either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d.or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance:usually 400-800 mg daily. Children under 6 years of age- Initial: 10-20 mg/kg/day b.i.d.or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Anleptic CR 200 mg for use at doses above 35 mg/kg/24 hours can be made. Combination therapy: Anleptic CR 200 mg may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased.Trigeminal Neuralgia: Initial: On the first day,either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or controlled release tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.Interaction of Anleptic CR 200 mgGalactorrhoea has been reported in few women on oral contraceptives within the first two months of Anleptic CR 200 mg treatment Hepatic enzyme inducers such as Anleptic CR 200 mg and Phenytoin may interact with Anleptic CR 200 mg by increasing its metabolism. So an increase in dosage of Anleptic CR 200 mg may be required.ContraindicationsThis medicine should not be used if anybody is allergic to one or any of its ingredients. It can not be used also in the following conditions: Problems with the electrical message pathways in the heart (atrioventricular block) History of decreased blood cell production by the bone marrow (bone marrow depression) Hereditary blood disorders called porphyrias Allergy to tricyclic antidepressants People who have taken a monoamine-oxidase inhibitor antidepressant (MAOI) in the last 14 days Side Effects of Anleptic CR 200 mgThe common side effects are dizziness, drowsiness, ataxia, dry mouth, abdominal pain, nausea, vomiting, anorexia, leucopenia, proteinuria, bradycardia, heart failure and hypotension. Erythematous skin rash, aplastic anemia may also be observed. The most severe adverse reactions have been observed in the hemopoietic system, the skin and the cardiovascular system.The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. This medicine may cause increased sensitivity to the sun. Exposure to the sun, sunlamps, or tanning booths should be avoided if the increased sensitivity is seen. A sunscreen or protective clothing may be helpful at outside for a prolonged period.Pregnancy & LactationPregnancy category D. Anleptic CR 200 mg and its epoxide metabolite are transferred to breast milk. Because of the potential serious side effects, decision should me made whether to discontinue nursing or discontinue the drug.Precautions & WarningsThis medicine may cause dizziness and drowsiness.Special care should be taken while performing potentially hazardous activities, such as driving or operating machinery.This medicine may cause skin reactions. If any rash,skin peeling, itching, or other unexplained skin reaction is seen while taking this medicine the concerned doctor should be informed immediately.This medicine may rarely cause liver problems.For this reason, consultation with doctor is needed if unexplained itching, yellowing of the skin or eyes, unusually dark urine, nausea and vomiting, abdominal pains, and loss of appetite or flu-like symptoms.Anleptic CR 200 mg decreases the blood levels of hormonal contraceptives containing estrogen and/or progesterone, which may make the contraceptive ineffective or result in breakthrough bleeding.Women taking this medicine who require contraception should be prescribed a contraceptive containing at least 50 micrograms of oestrogen,or use non-hormonal methods of contraception, such as condoms.Taking this medicine should not be stopped suddenly unless the doctor tells. Otherwise, as suddenly stopping treatment is likely to make the symptoms return.If this medicine is stopped, it should normally be done gradually, under the supervision of a specialist.Caution should be taken in- Mixed seizures including absence seizures Elderly people History of heart disease History of kidney disease History of liver disease History of psychotic illness Raised pressure in the eye (intraocular pressure), eg.glaucoma History of blood disorders that were caused by any other medication History of previous Anleptic CR 200 mg therapy that was interrupted due to side effects or allergy Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesPrimary anti-epileptic drugsMode Of ActionAnleptic CR 200 mg depresses activity in the nucleus ventralis of the thalamus, reduces synaptic propagation of excitatory impulses or decreases summation of temporal stimulation leading to neural discharge by limiting influx of Na ions across cell membrane or other unknown mechanisms. It stimulates the release of antidiuretic hormone (ADH) and potentiates its action in promoting reabsorption of water.PregnancyPregnancy category D. Anleptic CR 200 mg and its epoxide metabolite are transferred to breast milk. Because of the potential serious side effects, decision should me made whether to discontinue nursing or discontinue the drug.
Anleptic CR200 mg
Original price was: ₦331.10.₦298.10Current price is: ₦298.10. -
SaleAnleptic 100 mlAnleptic 100 ml is indicated for- partial and secondary generalized tonic-clonic seizures Primary generalized tonic-clonic seizures Trigeminal neuralgia Prophylaxis of bipolar disorder Theropeutic ClassPrimary anti-epileptic drugsPharmacologyAnleptic 100 ml depresses activity in the nucleus ventralis of the thalamus, reduces synaptic propagation of excitatory impulses or decreases summation of temporal stimulation leading to neural discharge by limiting influx of Na ions across cell membrane or other unknown mechanisms. It stimulates the release of antidiuretic hormone (ADH) and potentiates its action in promoting reabsorption of water.Dosage & Administration of Anleptic 100 mlEpilepsy: Adults and children over 12 years of age- Initial: Either 200 mg b.i.d. for tablets and controlled release tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Children 12-15 years of age- Dosage generally should not exceed 1000 mg daily, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: usually 800-1200 mg daily. Children 6-12 years of age- Initial: Either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d.or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance:usually 400-800 mg daily. Children under 6 years of age- Initial: 10-20 mg/kg/day b.i.d.or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Anleptic 100 ml for use at doses above 35 mg/kg/24 hours can be made. Combination therapy: Anleptic 100 ml may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased.Trigeminal Neuralgia: Initial: On the first day,either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or controlled release tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.Dosage of Anleptic 100 mlEpilepsy: Adults and children over 12 years of age- Initial: Either 200 mg b.i.d. for tablets and controlled release tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Children 12-15 years of age- Dosage generally should not exceed 1000 mg daily, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: usually 800-1200 mg daily. Children 6-12 years of age- Initial: Either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d.or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance:usually 400-800 mg daily. Children under 6 years of age- Initial: 10-20 mg/kg/day b.i.d.or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Anleptic 100 ml for use at doses above 35 mg/kg/24 hours can be made. Combination therapy: Anleptic 100 ml may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased.Trigeminal Neuralgia: Initial: On the first day,either 100 mg b.i.d. for tablets or controlled release tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or controlled release tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.Interaction of Anleptic 100 mlGalactorrhoea has been reported in few women on oral contraceptives within the first two months of Anleptic 100 ml treatment Hepatic enzyme inducers such as Anleptic 100 ml and Phenytoin may interact with Anleptic 100 ml by increasing its metabolism. So an increase in dosage of Anleptic 100 ml may be required.ContraindicationsThis medicine should not be used if anybody is allergic to one or any of its ingredients. It can not be used also in the following conditions: Problems with the electrical message pathways in the heart (atrioventricular block) History of decreased blood cell production by the bone marrow (bone marrow depression) Hereditary blood disorders called porphyrias Allergy to tricyclic antidepressants People who have taken a monoamine-oxidase inhibitor antidepressant (MAOI) in the last 14 days Side Effects of Anleptic 100 mlThe common side effects are dizziness, drowsiness, ataxia, dry mouth, abdominal pain, nausea, vomiting, anorexia, leucopenia, proteinuria, bradycardia, heart failure and hypotension. Erythematous skin rash, aplastic anemia may also be observed. The most severe adverse reactions have been observed in the hemopoietic system, the skin and the cardiovascular system.The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. This medicine may cause increased sensitivity to the sun. Exposure to the sun, sunlamps, or tanning booths should be avoided if the increased sensitivity is seen. A sunscreen or protective clothing may be helpful at outside for a prolonged period.Pregnancy & LactationPregnancy category D. Anleptic 100 ml and its epoxide metabolite are transferred to breast milk. Because of the potential serious side effects, decision should me made whether to discontinue nursing or discontinue the drug.Precautions & WarningsThis medicine may cause dizziness and drowsiness.Special care should be taken while performing potentially hazardous activities, such as driving or operating machinery.This medicine may cause skin reactions. If any rash,skin peeling, itching, or other unexplained skin reaction is seen while taking this medicine the concerned doctor should be informed immediately.This medicine may rarely cause liver problems.For this reason, consultation with doctor is needed if unexplained itching, yellowing of the skin or eyes, unusually dark urine, nausea and vomiting, abdominal pains, and loss of appetite or flu-like symptoms.Anleptic 100 ml decreases the blood levels of hormonal contraceptives containing estrogen and/or progesterone, which may make the contraceptive ineffective or result in breakthrough bleeding.Women taking this medicine who require contraception should be prescribed a contraceptive containing at least 50 micrograms of oestrogen,or use non-hormonal methods of contraception, such as condoms.Taking this medicine should not be stopped suddenly unless the doctor tells. Otherwise, as suddenly stopping treatment is likely to make the symptoms return.If this medicine is stopped, it should normally be done gradually, under the supervision of a specialist.Caution should be taken in- Mixed seizures including absence seizures Elderly people History of heart disease History of kidney disease History of liver disease History of psychotic illness Raised pressure in the eye (intraocular pressure), eg.glaucoma History of blood disorders that were caused by any other medication History of previous Anleptic 100 ml therapy that was interrupted due to side effects or allergy Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesPrimary anti-epileptic drugsMode Of ActionAnleptic 100 ml depresses activity in the nucleus ventralis of the thalamus, reduces synaptic propagation of excitatory impulses or decreases summation of temporal stimulation leading to neural discharge by limiting influx of Na ions across cell membrane or other unknown mechanisms. It stimulates the release of antidiuretic hormone (ADH) and potentiates its action in promoting reabsorption of water.PregnancyPregnancy category D. Anleptic 100 ml and its epoxide metabolite are transferred to breast milk. Because of the potential serious side effects, decision should me made whether to discontinue nursing or discontinue the drug.
Anleptic100 ml
Original price was: ₦16,549.50.₦14,894.55Current price is: ₦14,894.55. -
SaleAnorel This is indicated for- Internal and external hemorrhoids Post-partum hemorrhoidal condition Anal pruritus, peri-anal eczema, anal fissures and proctitis? Post-hemorrhoidectomy application to relieve pain and discomfort CompositionEach gram ointment contains- Cinchocaine Hydrochloride BP 5 mg Hydrocortisone USP 5 mg Neomycin Sulphate BP equivalent to 10 mg Neomycin Esculin Sesquihydrate equivalent to 10 mg Esculin Each suppository contains- Cinchocaine Hydrochloride BP 5 mg Hydrocortisone USP 5 mg Neomycin Sulphate BP equivalent to 10 mg Neomycin Esculin Sesquihydrate equivalent to 10 mg Esculin Theropeutic ClassCompound steroidal preparations, Drugs used in Ano-rectal regionPharmacologyCinchocaine is a local anesthetic which relieves severe pain and relaxes sphincteric spasm. Hydrocortisone acts as an anti-inflammatory and anti-pruritic agent and thereby eliminates itching and inflammation. Neomycin is a broad-spectrum antibiotic which eradicates most infections which may already be present or arise in lesions of the anorectal area. Esculin improves skin vasculature and is effective in management of cellulitis.Dosage & Administration of Anorel Ointment: A small quantity of the ointment should be applied with finger in the painful pruritic area in the morning and evening and after each stool. For deep application nozzle should be attached to the tube and inserted to full extent and should be squeezed gently from the lower end while withdrawing.Suppository: One suppository in the morning and one in the evening, and one after each stool.Use in children: Not recommended for children.Dosage of Anorel Ointment: A small quantity of the ointment should be applied with finger in the painful pruritic area in the morning and evening and after each stool. For deep application nozzle should be attached to the tube and inserted to full extent and should be squeezed gently from the lower end while withdrawing.Suppository: One suppository in the morning and one in the evening, and one after each stool.Use in children: Not recommended for children.ContraindicationsContraindicated in patients hypersensitive to any component of the product.Side Effects of Anorel Side effects which have been reported for individual constituents may occur and appropriate precautions should be taken when using this preparation.Pregnancy & LactationUse in pregnancy: The safe use of topical corticosteroids during pregnancy has not been fully established.Precautions & WarningsLike most of the steroids under certain circumstances hydrocortisone may be absorbed in sufficient amount to produce systemic effects. So, long term use should be avoided. Adrenal suppression may occur even without occlusion. When used for prolonged period striae may occur. Skin sensitisation may occur due to Neomycin. Absorption of the antibiotic from wound or inflamed skin may occur and this may affect the hearing irreversibly. Hence this preparation should not be given to extensively damaged skin.Storage ConditionsKeep in a cool dry place protected from light. Keep out of reach of children.Drug ClassesCompound steroidal preparations, Drugs used in Ano-rectal regionMode Of ActionCinchocaine is a local anesthetic which relieves severe pain and relaxes sphincteric spasm. Hydrocortisone acts as an anti-inflammatory and anti-pruritic agent and thereby eliminates itching and inflammation. Neomycin is a broad-spectrum antibiotic which eradicates most infections which may already be present or arise in lesions of the anorectal area. Esculin improves skin vasculature and is effective in management of cellulitis.PregnancyUse in pregnancy: The safe use of topical corticosteroids during pregnancy has not been fully established.
Anorel
Original price was: ₦4,416.50.₦3,974.85Current price is: ₦3,974.85. -
SaleAnquil 7.5 mgAnquil 7.5 mg is indicated in- Short-term treatment of insomnia. Sedation in premedication before surgical or diagnostic procedures. Theropeutic ClassBenzodiazepine hypnotics, Benzodiazepine sedativesPharmacologyAnquil 7.5 mg binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites w/in the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to Cl ions, which results in hyperpolarisation (a less excitable state) and stabilisation. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors.Dosage & Administration of Anquil 7.5 mgThe duration of treatment with oral Anquil 7.5 mg should not be more than of 2 weeks. In certain cases extension beyond the maximum treatment period may be necessary.Insomnia: Adults: 7.5 mg to 15 mg daily (Oral) Elderly: 7.5 mg daily?(Oral) Premedication: 7.5 mg to 15 mg, should be given 30-60 minutes before the procedure?(Oral) Endoscopic or Cardiovascular procedures: Adult: initial dose is 2.5 mg (IV) Elderly & debilitated patients: 1-1.5 mg (IV) Induction of Anesthesia: Adult: 10-15 mg (IV) or 0.07-0.1 mg/Kg body weight, usually 5 mg (IM) Children: 0.15-0.20 mg/Kg (IM) Elderly & debilitated patients: 0.025-0.05 mg/Kg (IM) Rectal administration in children: for preoperative sedation, rectal administration of the ampoule solution is 0.35-0.45 mg/Kg, 20-30 min before induction of general anesthesiaDosage of Anquil 7.5 mgOral dosage: For adults: 7.5-15 mg daily. In elderly and debilitated patients: The recommended dose is 7.5 mg. In premedication: 15 mg of Anquil 7.5 mg should be given 30-60 minutes before the procedure. Intravenous administration: Endoscopic or Cardiovascular Procedures: In healthy adults, the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg. Induction of Anesthesia: The dose is 10-15 mg. Intramuscular administration: Adult: 0.07-0.1 mg/kg body weight. The usual dose is about 5 mg. Children: 0.15-0.20 mg/kg Elderly and debilitated patients: 0.025-0.05 mg/kg Rectal administration in children: For preoperative sedation: Rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min. before induction of general anesthesia. Interaction of Anquil 7.5 mgAnquil 7.5 mg can enhance the central sedative effect of neuroleptics, tranquillizers, antidepressants, sleep-inducing drugs, analgesics, anaesthetics, antipsychotics, anxiolytics, antiepileptic drugs and sedative antihistamines.ContraindicationsAnquil 7.5 mg must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the productSide Effects of Anquil 7.5 mgAt the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Anquil 7.5 mg, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate.Pregnancy & LactationInsufficient data are available on Anquil 7.5 mg to assess its safety during pregnancy. But benzodiazepines adversely affect the human fetus. So their use should be avoided if there is safer alternative. Anquil 7.5 mg is excreted through breast milk. Therefore, Anquil 7.5 mg should not be used by the nursing mothers.Precautions & WarningsAnquil 7.5 mg IV should be administered very slowly.Overdose Effects of Anquil 7.5 mgExtreme overdosage may lead to coma, areflexia, cardiorespiratory depression and apnea. The effects of overdosage can be controlled with benzodiazepine antagonist flumazenil.Storage ConditionsProtect from light and moisture, store in cool and dry place. Keep out of the reach of children.Drug ClassesBenzodiazepine hypnotics, Benzodiazepine sedativesMode Of ActionThe actions of benzodiazepines such as Anquil 7.5 mg are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the central nervous system. Benzodiazepines increase the activity of GABA, thereby producing a sedating effect, relaxing skeletal muscles, and inducing sleep, anesthesia, and amnesia. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening. These receptors have been identified in different body tissues including the heart and skeletal muscle, although mainly appear to be present in the central nervous system.PregnancyAnquil 7.5 mg should be avoided during pregnancy unless there is no safer alternative. Since Anquil 7.5 mg passes into breast milk, it should not be administered to breast-feeding mothers.
Anquil7.5 mg
Original price was: ₦660.00.₦594.00Current price is: ₦594.00. -
SaleAnril SR 2.6 mgAnril SR 2.6 mg sublingual tablet is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery diseaseTheropeutic ClassNitrates: Coronary vasodilatorsPharmacologyAnril SR 2.6 mg forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle and result in vasodilatation.Dosage & Administration of Anril SR 2.6 mgOne sublingual tablet should be dissolved under the tongue at the first sign of an acute anginal attack. The dose may be repeated approximately every five minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, prompt medical attention is recommended.Interaction of Anril SR 2.6 mgPatients receiving antihypertensive drugs, beta-adrenergic blockers or phenothiazines and nitrates should be observed for possible additive hypotensive effects. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Concomitant use of nitrates and alcohol may cause hypotension. The vasodilatory and hemodynamic effects of Anril SR 2.6 mg may be enhanced by concomitant administration of aspirin. Patients receiving sublingual Anril SR 2.6 mg should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.ContraindicationsSublingual Anril SR 2.6 mg therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure and those with a known hypersensitivity to Anril SR 2.6 mg. Administration of Anril SR 2.6 mg is contraindicated in patients who are using sildenafil citrate since sildenafil citrate has been shown to potentiate the hypotensive effects of organic nitrates.Side Effects of Anril SR 2.6 mgHeadache which may be severe and persistent may occur immediately after use. Vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally.Pregnancy & LactationAnril SR 2.6 mg should be given to a pregnant woman only if clearly needed. It is not known whether Anril SR 2.6 mg is excreted in human milk.Precautions & WarningsOnly the smallest dose required for effective control of the acute anginal attack should be used. Excessive use may lead to the development of tolerance. This drug should be used with caution in patients who may be volume-depleted or are alredy hypotensive.Storage ConditionsStore in a cool and dry place away from light and heat. Keep all medicines out of the reach of children.
Anril SR2.6 mg
Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00. -
SaleAnril 400 mcgAnril 400 mcg sublingual tablet is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery diseaseTheropeutic ClassNitrates: Coronary vasodilatorsPharmacologyAnril 400 mcg forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle and result in vasodilatation.Dosage & Administration of Anril 400 mcgOne sublingual tablet should be dissolved under the tongue at the first sign of an acute anginal attack. The dose may be repeated approximately every five minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, prompt medical attention is recommended.Interaction of Anril 400 mcgPatients receiving antihypertensive drugs, beta-adrenergic blockers or phenothiazines and nitrates should be observed for possible additive hypotensive effects. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Concomitant use of nitrates and alcohol may cause hypotension. The vasodilatory and hemodynamic effects of Anril 400 mcg may be enhanced by concomitant administration of aspirin. Patients receiving sublingual Anril 400 mcg should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.ContraindicationsSublingual Anril 400 mcg therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure and those with a known hypersensitivity to Anril 400 mcg. Administration of Anril 400 mcg is contraindicated in patients who are using sildenafil citrate since sildenafil citrate has been shown to potentiate the hypotensive effects of organic nitrates.Side Effects of Anril 400 mcgHeadache which may be severe and persistent may occur immediately after use. Vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally.Pregnancy & LactationAnril 400 mcg should be given to a pregnant woman only if clearly needed. It is not known whether Anril 400 mcg is excreted in human milk.Precautions & WarningsOnly the smallest dose required for effective control of the acute anginal attack should be used. Excessive use may lead to the development of tolerance. This drug should be used with caution in patients who may be volume-depleted or are alredy hypotensive.Storage ConditionsStore in a cool and dry place away from light and heat. Keep all medicines out of the reach of children.
Anril400 mcg
Original price was: ₦14,850.00.₦13,365.00Current price is: ₦13,365.00. -
SaleAnset 4 mg/5 mlAnset 4 mg/5 ml is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting. Prevention of radiotherapy-induced nausea and vomiting. Theropeutic ClassAnti-emetic drugsPharmacologyAnset 4 mg/5 ml is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Anset 4 mg/5 ml is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Anset 4 mg/5 ml's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.Dosage & Administration of Anset 4 mg/5 mlPrevention of chemotherapy induced nausea & vomiting (CINV): Adult- Tablet and oral solution: The recommended adult oral dosage of Anset 4 mg/5 ml is 24 mg given as three 8 mg tablets in highly emetogenic chemotherapy. In case of moderately emetogenic chemotherapy the oral dose is one 8 mg Anset 4 mg/5 ml tablet or 10 ml of Anset 4 mg/5 ml oral solution given twice daily. Injection: The recommended i.v. dose of Anset 4 mg/5 ml is a single 32 mg dose or three 0.15 mg/kg doses. A single 32 mg dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of Anset 4 mg/5 ml. Suppository: The recommended adult dose is one 16 mg suppository 1-2 hours before treatment. Anset 4 mg/5 ml should be continued for upto 5 days after a course of treatment.The recommended dose is one suppository daily. Pediatric patients- Tablet and oral solution:?for pediatric patients 4 through 11 years of age the dosage is one 4 mg Anset 4 mg/5 ml tablet or 5ml of Anset 4 mg/5 ml solution should be administered 3 times a day for 1 to 2 days after completion of chemotherapy. Injection: the dosage in pediatric patients 4 to 18 years of age should three 0.15-mg/kg doses. Suppository:Not recommended. Radiotherapy induced nausea and vomiting: Adult: the recommended oral dosage is one 8mg Anset 4 mg/5 ml tablet or 10ml of Anset 4 mg/5 ml oral solution given 3 times daily. Post operative nausea & vomiting: Adult- Tablet and oral solution: The recommended dosage is 16 mg given as two 8 mg Anset 4 mg/5 ml tablets or 20 ml of Anset 4 mg/5 ml oral solution 1hour before induction of anesthesia. Injection: The recommended I.V. dosage of Anset 4 mg/5 ml for adults is 4 mg undiluted administered intravenously in not less than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient experiences nausea and/or vomiting occurring shortly after surgery. Alternatively, 4 mg undiluted may be administered intramuscularly as a single injection for adults. In patients who do not achieve adequate control of postoperative nausea and vomiting following a single, prophylactic, preinduction, I.V. dose of Anset 4 mg/5 ml 4 mg, administration of a second I.V. dose of 4 mg Anset 4 mg/5 ml postoperatively does not provide additional control of nausea and vomiting. Suppository: The recommended adult dose is one 16 mg suppository 1-2 hours before treatment. Anset 4 mg/5 ml should be continued for upto 5 days after a course of treatment.The recommended dose is one suppository daily. Pediatric patients- Injection: The recommended I.V. dosage of Anset 4 mg/5 ml for pediatric patients (2 to 12 years of age) is?a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or a single 4 mg dose for pediatric patients weighing more than 40 kg. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Little information is available about dosage in pediatric patients younger than 2 years of age. Suppository: Not recommended. Dosage of Anset 4 mg/5 mlChemotherapy-Induced Nausea and Vomiting-Adults, Pediatric patients (6 months to 18 years): 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. Radiotherapy-Induced Nausea and Vomiting-Adults: 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment. 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. Postoperative Nausea and Vomiting-Adults: 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets 4 mg orodispersible tablet: 16 mg Injection: 4 mg Pediatrics (>40 kg): Injection: 4 mgPediatrics (40 kg): Injection: 0.1 mg/kgChemotherapy-induced Nausea and Vomiting-Adults/Geriatric/Child of 12 years or over: Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Anset 4 mg/5 ml Oral Solution administered 30 minutes before start of emetogenic chemotherapy. Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Anset 4 mg/5 ml Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy. Pediatric (4-11 years): 5 ml (4 mg) Anset 4 mg/5 ml Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy. Oral solution: Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over): The recommended oral dosage: 10 ml (8 mg) Anset 4 mg/5 ml Oral Solution 3 times daily. For total body irradiation: 10 ml (8-mg) Anset 4 mg/5 ml Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day. For single high-dose fraction radiotherapy to the abdomen: one 10 ml Anset 4 mg/5 ml Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Anset 4 mg/5 ml Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given. Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over): 20 ml (16 mg) Anset 4 mg/5 ml Oral Solution 1 hour before induction of anesthesia Oral Soluble Film: Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy: Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy: Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy. Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day. Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia. Administration of Anset 4 mg/5 mlAdministration of Oral Soluble Film: Step 1:?Tear the pouch carefully along with the edge tear mark. Step 2:?Put the Anset 4 mg/5 ml?film on top of your tongue. It will dissolve within 20 seconds Step 3:?Do not chew or swallow the film whole. Step 4:?Swallow after the Onsaf oral soluble film dissolves. You may swallow the dissolved film with or without liquid. Step 5:?Wash your hands after taking Onsaf oral soluble film Interaction of Anset 4 mg/5 mlAnset 4 mg/5 ml does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Anset 4 mg/5 ml is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Anset 4 mg/5 ml. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.ContraindicationsContraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.Side Effects of Anset 4 mg/5 mlFrequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Anset 4 mg/5 ml. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Anset 4 mg/5 ml is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Anset 4 mg/5 ml and placebo groups.Pregnancy & LactationPregnancy category B. Reproduction studies at daily oral dose up to 10 and 30 mg/kg/day have been performed in animals and have revealed no evidence of impaired fertility harm to the fetus due to Anset 4 mg/5 ml. There are, however, no adequate and well-controlled studies in pregnant women. So the drug should be used in pregnancy only if clearly needed. Anset 4 mg/5 ml excretes in milk of lactating animals. Caution should be exercised when Anset 4 mg/5 ml is administered to nursing mother.Precautions & WarningsHypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Anset 4 mg/5 ml is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Anset 4 mg/5 ml in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.Overdose Effects of Anset 4 mg/5 mlThere is no specific antidote for Anset 4 mg/5 ml overdose. In addition to the adverse events, hypotension (and faintness) occurred in a patient that took 48 mg of AVONA tablets. In all instances, the events resolved completely.Storage ConditionsStore at temperature not exceeding 30?C in a dry place. Protect from light and moisture.Use In Special PopulationsPediatric use: Can be given in children 1 month of age and above. Geriatric use: No dosage adjustment is necessary in the elderly.Dosage adjustment for patients with impaired hepatic function: Tablet and Oral Solution:?The total daily dose of 8 mg should not be exceeded. Injection:?A single maximal dose of 8 mg to be infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. Suppository: Not recommended ReconstitutionPrior to IV infusion, dilute in 50 ml dextrose 5% inj or normal saline.Drug ClassesAnti-emetic drugsMode Of ActionAnset 4 mg/5 ml is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Anset 4 mg/5 ml blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of Anset 4 mg/5 ml in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.PregnancyCarcinogenic effects were not seen in 2-year studies in rats and mice with oral Anset 4 mg/5 ml doses up to 10 and 30 mg/kg per day, respectively. Anset 4 mg/5 ml was not mutagenic in standard tests for mutagenicity. Oral administration of Anset 4 mg/5 ml up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Anset 4 mg/5 ml. There are, however, no adequate and well-controlled studies in pregnant women. Anset 4 mg/5 ml is excreted in the breast milk of rats. So caution should be exercised when Anset 4 mg/5 ml is administered to a nursing women.Pediatric UsesDosage Adjustment for Patients With Impaired Renal Function: The dosage recommendation is the same as for the general population.Dosage Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic impairment, a single maximal daily dose of 8 mg to be infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended.4 years of age or younger: Little information is available about dosage in pediatric patients 4 years of age or younger.Over the age of 65: Dosage adjustment is not needed in patients over the age of 65.
Anset4 mg/5 ml
Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00. -
SaleAnset 8 mgAnset 8 mg is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting. Prevention of radiotherapy-induced nausea and vomiting. Theropeutic ClassAnti-emetic drugsPharmacologyAnset 8 mg is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Anset 8 mg is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Anset 8 mg's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.Dosage & Administration of Anset 8 mgPrevention of chemotherapy induced nausea & vomiting (CINV): Adult- Tablet and oral solution: The recommended adult oral dosage of Anset 8 mg is 24 mg given as three 8 mg tablets in highly emetogenic chemotherapy. In case of moderately emetogenic chemotherapy the oral dose is one 8 mg Anset 8 mg tablet or 10 ml of Anset 8 mg oral solution given twice daily. Injection: The recommended i.v. dose of Anset 8 mg is a single 32 mg dose or three 0.15 mg/kg doses. A single 32 mg dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of Anset 8 mg. Suppository: The recommended adult dose is one 16 mg suppository 1-2 hours before treatment. Anset 8 mg should be continued for upto 5 days after a course of treatment.The recommended dose is one suppository daily. Pediatric patients- Tablet and oral solution:?for pediatric patients 4 through 11 years of age the dosage is one 4 mg Anset 8 mg tablet or 5ml of Anset 8 mg solution should be administered 3 times a day for 1 to 2 days after completion of chemotherapy. Injection: the dosage in pediatric patients 4 to 18 years of age should three 0.15-mg/kg doses. Suppository:Not recommended. Radiotherapy induced nausea and vomiting: Adult: the recommended oral dosage is one 8mg Anset 8 mg tablet or 10ml of Anset 8 mg oral solution given 3 times daily. Post operative nausea & vomiting: Adult- Tablet and oral solution: The recommended dosage is 16 mg given as two 8 mg Anset 8 mg tablets or 20 ml of Anset 8 mg oral solution 1hour before induction of anesthesia. Injection: The recommended I.V. dosage of Anset 8 mg for adults is 4 mg undiluted administered intravenously in not less than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient experiences nausea and/or vomiting occurring shortly after surgery. Alternatively, 4 mg undiluted may be administered intramuscularly as a single injection for adults. In patients who do not achieve adequate control of postoperative nausea and vomiting following a single, prophylactic, preinduction, I.V. dose of Anset 8 mg 4 mg, administration of a second I.V. dose of 4 mg Anset 8 mg postoperatively does not provide additional control of nausea and vomiting. Suppository: The recommended adult dose is one 16 mg suppository 1-2 hours before treatment. Anset 8 mg should be continued for upto 5 days after a course of treatment.The recommended dose is one suppository daily. Pediatric patients- Injection: The recommended I.V. dosage of Anset 8 mg for pediatric patients (2 to 12 years of age) is?a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or a single 4 mg dose for pediatric patients weighing more than 40 kg. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Little information is available about dosage in pediatric patients younger than 2 years of age. Suppository: Not recommended. Dosage of Anset 8 mgChemotherapy-Induced Nausea and Vomiting-Adults, Pediatric patients (6 months to 18 years): 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. Radiotherapy-Induced Nausea and Vomiting-Adults: 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment. 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose. Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. Postoperative Nausea and Vomiting-Adults: 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets 4 mg orodispersible tablet: 16 mg Injection: 4 mg Pediatrics (>40 kg): Injection: 4 mgPediatrics (40 kg): Injection: 0.1 mg/kgChemotherapy-induced Nausea and Vomiting-Adults/Geriatric/Child of 12 years or over: Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Anset 8 mg Oral Solution administered 30 minutes before start of emetogenic chemotherapy. Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Anset 8 mg Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy. Pediatric (4-11 years): 5 ml (4 mg) Anset 8 mg Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy. Oral solution: Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over): The recommended oral dosage: 10 ml (8 mg) Anset 8 mg Oral Solution 3 times daily. For total body irradiation: 10 ml (8-mg) Anset 8 mg Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day. For single high-dose fraction radiotherapy to the abdomen: one 10 ml Anset 8 mg Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Anset 8 mg Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given. Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over): 20 ml (16 mg) Anset 8 mg Oral Solution 1 hour before induction of anesthesia Oral Soluble Film: Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy: Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy: Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy. Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day. Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia. Administration of Anset 8 mgAdministration of Oral Soluble Film: Step 1:?Tear the pouch carefully along with the edge tear mark. Step 2:?Put the Anset 8 mg?film on top of your tongue. It will dissolve within 20 seconds Step 3:?Do not chew or swallow the film whole. Step 4:?Swallow after the Onsaf oral soluble film dissolves. You may swallow the dissolved film with or without liquid. Step 5:?Wash your hands after taking Onsaf oral soluble film Interaction of Anset 8 mgAnset 8 mg does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Anset 8 mg is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Anset 8 mg. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.ContraindicationsContraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.Side Effects of Anset 8 mgFrequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Anset 8 mg. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Anset 8 mg is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Anset 8 mg and placebo groups.Pregnancy & LactationPregnancy category B. Reproduction studies at daily oral dose up to 10 and 30 mg/kg/day have been performed in animals and have revealed no evidence of impaired fertility harm to the fetus due to Anset 8 mg. There are, however, no adequate and well-controlled studies in pregnant women. So the drug should be used in pregnancy only if clearly needed. Anset 8 mg excretes in milk of lactating animals. Caution should be exercised when Anset 8 mg is administered to nursing mother.Precautions & WarningsHypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Anset 8 mg is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Anset 8 mg in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.Overdose Effects of Anset 8 mgThere is no specific antidote for Anset 8 mg overdose. In addition to the adverse events, hypotension (and faintness) occurred in a patient that took 48 mg of AVONA tablets. In all instances, the events resolved completely.Storage ConditionsStore at temperature not exceeding 30?C in a dry place. Protect from light and moisture.Use In Special PopulationsPediatric use: Can be given in children 1 month of age and above. Geriatric use: No dosage adjustment is necessary in the elderly.Dosage adjustment for patients with impaired hepatic function: Tablet and Oral Solution:?The total daily dose of 8 mg should not be exceeded. Injection:?A single maximal dose of 8 mg to be infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. Suppository: Not recommended ReconstitutionPrior to IV infusion, dilute in 50 ml dextrose 5% inj or normal saline.Drug ClassesAnti-emetic drugsMode Of ActionAnset 8 mg is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Anset 8 mg blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of Anset 8 mg in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.PregnancyCarcinogenic effects were not seen in 2-year studies in rats and mice with oral Anset 8 mg doses up to 10 and 30 mg/kg per day, respectively. Anset 8 mg was not mutagenic in standard tests for mutagenicity. Oral administration of Anset 8 mg up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Anset 8 mg. There are, however, no adequate and well-controlled studies in pregnant women. Anset 8 mg is excreted in the breast milk of rats. So caution should be exercised when Anset 8 mg is administered to a nursing women.Pediatric UsesDosage Adjustment for Patients With Impaired Renal Function: The dosage recommendation is the same as for the general population.Dosage Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic impairment, a single maximal daily dose of 8 mg to be infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended.4 years of age or younger: Little information is available about dosage in pediatric patients 4 years of age or younger.Over the age of 65: Dosage adjustment is not needed in patients over the age of 65.
Anset8 mg
Original price was: ₦6,050.00.₦5,445.00Current price is: ₦5,445.00. -
SaleAnsulin N 100 IU/mlTreatment of all patients with type 1 diabetes. Treatment of patients with type 2 diabetes who are not adequately controlled by diet and/ or oral hypoglycemic agents. For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and during periods of stress such as severe infections and major surgery in diabetic patients. Treatment of gestational diabetes.Theropeutic ClassLong Acting InsulinPharmacologyThe blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulatard is a long-acting insulin. Onset of action is within 1? hours, reaches a maximum effect within 4-12 hours and the entire time of duration is approximately 24 hours.Insulin in the blood stream has a half-life of a few minutes. Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics. This process is influenced by several factors (e.g. insulin dosage, injection route and site, thickness of subcutaneous fat, type of diabetes). The pharmacokinetics of insulins is therefore affected by significant intra- and inter-individual variationDosage of Ansulin N 100 IU/mlDosage is individual and determined in accordance with the needs of the patient. The individual insulin requirement is usually between 0.3 and 1.0 IU/kg day. The daily insulin requirement may be higher in patients with insulin resistance (e.g. during puberty or due to obesity) and lower in patients with residual, endogenous insulin production.The physician determines one or several daily injections are necessary. Insulatard may be used alone or mixed with fast-acting insulin. In intensive insulin therapy the suspension may be used as basal insulin (evening and/or morning injection) with fast-acting insulin given at meals. In patients with diabetes mellitus optimised glycaemic control delays the onset of late diabetic complications. Close blood glucose monitoring is recommended.Administration of Ansulin N 100 IU/mlFor subcutaneous use. Insulatard is usually administered subcutaneously in the thigh. If convenient, the abdominal wall, the gluteal region or the deltoid region may also be used. Subcutaneous injection into the thigh results in a slower and less variable absorption compared to the other injection sites. Injection into a lifted skin fold minimises the risk of unintended intramuscular injection.Keep the needle under the skin for at least 6 seconds to make sure the entire dose is injected. Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy. Insulin suspensions are never to be administered intravenously. Insulatard is accompanied by a package leaflet with detailed instruction for use to be followed. The vials are for use with insulin syringes with corresponding unit scale. When two types of insulin are mixed, draw the amount of fast-acting insulin first, followed by the amount of long-acting insulinInteraction of Ansulin N 100 IU/mlA number of medicinal products are known to interact with the glucose metabolism. Physicians must therefore take possible interactions into account and should always ask their patients about any medicinal products they take.The following substances may reduce insulin requirement: Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta-blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates and alcohol.The following substances may increase insulin requirement: Thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol. Beta-blocking agents may mask the symptoms of hypoglycaemia and delay recovery from hypoglycaemia. Octreotide/lanreotide may both decrease and increase insulin requirement. Alcohol may intensify and prolong the hypoglycaemic effect of insulin.ContraindicationsHypoglycaemia, Hypersensitivity to human insulin or to any of the excipientsSide Effects of Ansulin N 100 IU/mlHypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique.Pregnancy & LactationThere are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier.Precautions & WarningsInadequate dosage or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. Usually the first symptoms of hyperglycaemia set in gradually, over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal. Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirementOmission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia. Patients whose blood glucose control is greatly improved e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly Usual warning symptoms may disappear in patients with longstanding diabetes.Overdose Effects of Ansulin N 100 IU/mlA specific overdose of insulin cannot be defined. However, hypoglycaemia may develop over sequential stagesStorage ConditionsStore in a refrigerator (2?C-8?C). Do not freeze. Keep the container cartridge or vial in the outer carton in order to protect from light.During use: do not refrigerate. Do not store vials above 25?C and cartridges above 30?C. Protect from excessive heat and sunlight.
Ansulin N100 IU/ml
Original price was: ₦22,825.00.₦20,542.50Current price is: ₦20,542.50. -
SaleAnsulin R Vial 100 IU/mlTreatment of all type 1 diabetic patient. treatment for those with type 2 diabetes whose blood sugar cannot be sufficiently controlled by diet or oral hypoglycemic medications. for the initial stabilization of diabetes in people with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome, and during stressful times like serious illnesses and major surgery for people with diabetes. gestational diabetes treatment.Theropeutic ClassRapid Acting InsulinPharmacologyThe ability of insulin to connect to receptors on muscle and fat cells and to simultaneously restrict the liver's ability to release glucose are what cause it to drop blood sugar levels. Long-acting insulin is called Insulatard. The action begins within one and a half hours, has its peak effect within four to twelve hours, and lasts for roughly twenty-four hours. The half-life of insulin in the blood is only a few minutes. As a result, only the features of an insulin preparation's absorption dictate its time-action profile. Many elements have an impact on this process (e.g. insulin dosage, injection route, and site, the thickness of subcutaneous fat, and type of diabetes).Dosage of Ansulin R Vial 100 IU/mlUse your insulin exactly as directed by your doctor, adjusting the dosage as necessary. If you're unsure, ask your doctor, pharmacist, or nurse. Within 30 minutes of the injection, consume a meal or snack that contains carbs to prevent low blood sugar. If your doctor doesn't instruct you to, don't adjust your insulin. Your doctor may need to change your dose if you were switched from one brand or kind of insulin to another.Administration of Ansulin R Vial 100 IU/mlfor usage beneath the skin. Typically, Insulatard is injected subcutaneously into the thigh. If more practical, the deltoid area, gluteal area, or abdominal wall may also be employed. In comparison to the other injection locations, the thigh's subcutaneous injection causes a slower and less varied absorption. Unintentional intramuscular injection is less likely when the skin fold is injected into. To ensure that the entire dosage is injected, keep the needle subcutaneously for at least 6 seconds. To prevent lipodystrophy, injection sites should be rotated within anatomical regions. Never inject insulin suspensions intravenously. A package booklet for Insulatard contains comprehensive usage instructions that must be followed. The vials are meant to be used with equivalent unit insulin syringes. When two types of insulin are mixed, draw the amount of fast-acting insulin first, followed by the amount of long-acting insulin.Side Effects of Ansulin R Vial 100 IU/mlHypoglycemia, or low blood sugar, is a relatively frequent adverse consequence. More than one in ten persons might be impacted. Low blood sugar symptoms include cold perspiration, chilly pale skin, headache, rapid heartbeat, nausea, extreme hunger, brief changes in vision, fatigue, unusual weakness, anxiety or tremor, feeling agitated, feeling confused, and difficulty focusing.Pregnancy & LactationBefore using this medication, consult your doctor if you are pregnant, suspect you may be pregnant, or are planning a pregnancy. You can use this insulin while you're pregnant. You might need to adjust your insulin dosage both during pregnancy and after birth. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby. The use of this insulin during breastfeeding is not restricted.Precautions & WarningsIf you experience issues with your adrenal, pituitary, thyroid, or liver glands. If you decide to vary your typical diet or engage in more exercise than usual, as these actions may have an impact on your blood sugar level. Continue taking your insulin and see a doctor if you feel sick. Traveling across time zones when visiting another country could change your demand for insulin and the timing of this.Storage ConditionsKeep refrigerated at 2?C to 8?C. Avoid touching the cooling device. Avoid freezing.Use In Special PopulationsUsage in children and adolescents: Children and adolescents may use this. Usage with specific patient populations You should check your blood sugar more frequently and talk to your doctor about adjusting your insulin dosage if you have impaired kidney or liver function or if you are over 65.
Ansulin R Vial100 IU/ml
Original price was: ₦22,825.00.₦20,542.50Current price is: ₦20,542.50. -
SaleAnsulin 30%+70% in 100 IU/mlTreatment of all type 1 diabetic patient. Treatment for those with type 2 diabetes whose blood sugar cannot be sufficiently controlled by diet or oral hypoglycemic medications. For the initial stabilization of diabetes in people with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome, and during stressful times like serious illnesses and major surgery for people with diabetes. Gestational diabetes treatment.CompositionIsophane Insulin Human 30/70 Injection with Insulin Human (rDNA) Insulin Human (rDNA) USP 40 IU (equal to 1.388 mg) is present in each milliliter of solution as 30% Soluble Insulin Human (Regular) and 70% Isophane Insulin Human. Isophane Insulin Human 30/70 Injection with Insulin Human (rDNA) Insulin Human (rDNA) USP 100 IU (equal to 3.47 mg) is present in each milliliter of solution as 30% Soluble Insulin Human (Regular) and 70% Isophane Insulin Human. 50/50 Injection of Insulin Human (rDNA) and Isophane Insulin Human (rDNA) USP 100 IU (equal to 3.47 mg) is present in each milliliter of solution as 50% soluble Insulin Human (Regular) and 50% isophane Insulin Human.Theropeutic ClassInsulin with a Medium Action.PharmacologyHuman insulin is produced using recombinant DNA technology as Insulin Human (rDNA). It works and is structurally identical to natural insulin. Insulin controls how glucose is metabolized and promotes the absorption and use of glucose by the liver, muscles, and fat. By promoting glycogenesis and preventing gluconeogenesis, it also reduces blood sugar levels. After injection, insulin human (rDNA) 30/70 and insulin human (rDNA) 50/50 begin to work within 30 minutes, reach their peak levels between 2 and 8 hours later, and persist for roughly 24 hours.Dosage of Ansulin 30%+70% in 100 IU/mlThe average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction.Administration of Ansulin 30%+70% in 100 IU/mlWithin 30 minutes of an injection, a meal or snack containing carbs should be had. Subcutaneous injections are given in the upper arm, thigh, buttock, or abdominal wall. More quickly than from other injection locations, the abdominal wall receives a subcutaneous injection. Never inject insulin human (rDNA) 30/70 or insulin human (rDNA) 50/50 intravenously. Getting ready for use: Sanitize your hands. To evenly mix the solution and see if the insulin looks normal, gently shake or rotate the vial. When using a brand-new vial, remove the plastic protective cap and use an alcohol swab to clean the rubber plug. Add air to your syringe in an amount equal to the required amount of insulin. Inject air by sticking the needle into the vial. Draw the appropriate amount of insulin into the syringe while turning the bottle and syringe upside down. Check to see if there are any bubbles left in the syringe before removing the needle. In that case, hold the syringe upright and tap it to release the air bubbles. Injection site: Choose the region of the body with looser-fitting skin, such as the upper arm, thigh, buttock, or abdomen. Choose a location for each injection that is at least 1 cm away from the location of the preceding injection to prevent tissue injury. Injection method: Wash the area of the skin where the injection will be made with alcohol. Place the needle so that it forms a 45? angle with the skin. Injecting insulin requires puncturing the skin with a needle. To ensure that the entire dosage is injected, keep the needle subcutaneous for at least 6 seconds. After removing the needle, place mild pressure on the injection site for several seconds. Avoid scratching the injection site.Interaction of Ansulin 30%+70% in 100 IU/mlWhen taking oral contraceptives, thyroid hormone, adrenal cortical hormone, and other medications that can cause blood sugar levels to rise, you may need to take more insulin. Reduced insulin dosage is necessary when using antidepressants such as salicylate, sulfanilamide, and others that have hypoglycemic effects and cause a drop in blood sugar levels.ContraindicationsPatients with hypoglycemia or those who are allergic to insulin or any of the excipients.Side Effects of Ansulin 30%+70% in 100 IU/mlThe most frequent unfavorable consequence of insulin therapy is hypoglycemia, and its symptoms might strike rapidly. There aren't many occurrences of allergic reactions that cause red, puffy, or itchy skin. It typically goes away after a few days. In rare cases, factors other than insulin, such as disinfectant and improper injection technique, may be to blame for the allergy.Pregnancy & LactationBecause insulin cannot cross the placental barrier, there are no limits on using it to treat diabetes during pregnancy. Baby safety is unaffected by the mother's insulin medication.Precautions & WarningsHyperglycemia may result from improper dosing or stopping the medication, particularly in type 1 diabetes. If the insulin dose is excessively high compared to the amount of insulin needed, hypoglycemia could result. Hypoglycemia can result from skipping meals or unexpectedly doing hard physical activity.Overdose Effects of Ansulin 30%+70% in 100 IU/mlHypoglycemia during treatment may result from using too much insulin. Hypoglycemia between mild and moderate may strike suddenly. When hypoglycemia strikes, it is crucial to seek immediate medical attention. If you have hypoglycemia frequently, speak with your doctor about any potential adjustments to your therapy, diet, and/or exercise regimen that may be necessary to help you stay hypoglycemic-free.Storage ConditionsKeeping in a refrigerator, store between 2 and 8 degrees Celsius. Never freeze. If insulin is being used recently and does not need to be refrigerated, try to keep it in a cool area away from heat and light. The currently-in-use insulin can be stored at room temperature for a month.
Ansulin30%+70% in 100 IU/ml
Original price was: ₦12,210.00.₦10,989.00Current price is: ₦10,989.00.